Gilead Sciences vs Incyte
Gilead Sciences (GILD) and Incyte (INCY) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $187B
- Last close
- $150.43
- 12 months
- +28.4%
- Market value
- $22.6B
- Last close
- $111.36
- 12 months
- +32.9%
At a glance
- By market value, Gilead Sciences ($186.5B) is about 8.3 times Incyte ($22.6B).
- Over the last 12 months Gilead Sciences's share price moved +28.4% and Incyte's +32.9%; against the S&P 500 that is +9.2 points and +13.7 points.
- In their last fiscal years Gilead Sciences kept 28.9% of revenue as net income and Incyte 25.0%.
- In the last 90 days insiders reported 0 open-market purchases at Gilead Sciences and 0 at Incyte; members of Congress disclosed 1 trade in Gilead Sciences and 0 in Incyte.
- Next results: Gilead Sciences Oct 22, 2026, Incyte Oct 29, 2026.
Share price over the last 12 months
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Gilead Sciences GILDNASDAQ · Biotechnology | Incyte INCYNASDAQ · Biotechnology | |
|---|---|---|
| Size and profitability | ||
| Market value | $187B | $22.6B |
| Revenue, last fiscal year | $29.4B | $5.14B |
| Net income, last fiscal year | $8.51B | $1.29B |
| Net marginNet income as a share of revenue | 28.9% | 25.0% |
| Free cash flow | $9.46B | $1.41B |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Gilead Sciences against
Common questions
How do Gilead Sciences and Incyte compare in size?
Gilead Sciences has the larger market value: Gilead Sciences $187B and Incyte $22.6B, at the last close.
Whose share price rose more over the last 12 months, GILD or INCY?
Over the last 12 months Gilead Sciences moved +28.4% and Incyte +32.9%. Past price moves say nothing about the future.
Which has had more insider buying, Gilead Sciences or Incyte?
Since 2006, Incyte insiders reported 503 open-market purchases against 8 for Gilead Sciences. These are counts of what was filed, not a view on either stock.
Do members of Congress trade GILD or INCY?
In the last 12 months, members of Congress disclosed 4 trades in Gilead Sciences (GILD) and 0 in Incyte (INCY).
When did insiders last buy GILD and INCY?
Gilead Sciences: Feb 6, 2015. Incyte: Mar 10, 2022.
See the record behind any of these
Each company page opens free with one real filing and the counts of the last 12 months. OQRO Pro adds the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Gilead Sciences pageIncyte pageRare insider trades this weekAll comparisons
https://oqro.io/compare/gild-vs-incy
